[go: up one dir, main page]

ECSP109966A - Derivados de 6-fenil-1h-imidazo-[4,5-c] piridina-4-carbonitrilo como inhibidores de catepsina - Google Patents

Derivados de 6-fenil-1h-imidazo-[4,5-c] piridina-4-carbonitrilo como inhibidores de catepsina

Info

Publication number
ECSP109966A
ECSP109966A EC2010009966A ECSP109966A ECSP109966A EC SP109966 A ECSP109966 A EC SP109966A EC 2010009966 A EC2010009966 A EC 2010009966A EC SP109966 A ECSP109966 A EC SP109966A EC SP109966 A ECSP109966 A EC SP109966A
Authority
EC
Ecuador
Prior art keywords
derivatives
phenyl
carbonitrile
piridina
catepsin
Prior art date
Application number
EC2010009966A
Other languages
English (en)
Inventor
Jiaqiang Cai
Zoran Rankovic
Philip Stephen Jones
David Jonathan Bennett
Xavier Fradera
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of ECSP109966A publication Critical patent/ECSP109966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a derivados de 6-fenil-1H-imidazol[4,5-c]piridina-4-carbonitrilo teniendo la Formula general (I), a composiciones farmacéuticas que los comprenden, así como también al uso de estos derivados para la preparación de un medicamento para el tratamiento de enfermedades relacionadas con catepsina S, tales como arterioesclerosis, obesidad, desordenes inflamatorios e inmunes, tales como artritis reumática, psoriais, cancer y dolor crónico, tal como el dolor neuropático.
EC2010009966A 2007-07-16 2010-02-12 Derivados de 6-fenil-1h-imidazo-[4,5-c] piridina-4-carbonitrilo como inhibidores de catepsina ECSP109966A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112517 2007-07-16

Publications (1)

Publication Number Publication Date
ECSP109966A true ECSP109966A (es) 2010-03-31

Family

ID=38846911

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009966A ECSP109966A (es) 2007-07-16 2010-02-12 Derivados de 6-fenil-1h-imidazo-[4,5-c] piridina-4-carbonitrilo como inhibidores de catepsina

Country Status (20)

Country Link
EP (1) EP2178873B1 (es)
JP (1) JP5371976B2 (es)
KR (1) KR20100043235A (es)
CN (1) CN101842373B (es)
AR (1) AR067530A1 (es)
AT (1) ATE492546T1 (es)
AU (1) AU2008277679B2 (es)
BR (1) BRPI0813587A2 (es)
CA (1) CA2693887A1 (es)
CL (1) CL2008002082A1 (es)
DE (1) DE602008004167D1 (es)
EC (1) ECSP109966A (es)
ES (1) ES2356279T3 (es)
HK (1) HK1142323A1 (es)
IL (1) IL202769A0 (es)
PE (1) PE20091087A1 (es)
RU (1) RU2485119C2 (es)
TW (1) TW200911803A (es)
WO (1) WO2009010491A1 (es)
ZA (1) ZA200909132B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) * 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
JP5792128B2 (ja) 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
JP6172143B2 (ja) 2012-04-17 2017-08-02 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
US11969418B2 (en) 2020-01-20 2024-04-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS)
EP3858471A1 (en) 2020-01-31 2021-08-04 Novamem AG Solvent-free production of porous polymer structures
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
FR2852957B1 (fr) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
TW200734338A (en) * 2006-01-16 2007-09-16 Organon Nv 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives

Also Published As

Publication number Publication date
EP2178873A1 (en) 2010-04-28
BRPI0813587A2 (pt) 2014-12-30
DE602008004167D1 (en) 2011-02-03
KR20100043235A (ko) 2010-04-28
CN101842373B (zh) 2013-12-18
EP2178873B1 (en) 2010-12-22
ATE492546T1 (de) 2011-01-15
CL2008002082A1 (es) 2009-01-02
WO2009010491A1 (en) 2009-01-22
ES2356279T3 (es) 2011-04-06
CN101842373A (zh) 2010-09-22
ZA200909132B (en) 2010-08-25
JP5371976B2 (ja) 2013-12-18
AR067530A1 (es) 2009-10-14
RU2010105234A (ru) 2011-08-27
AU2008277679B2 (en) 2012-11-15
TW200911803A (en) 2009-03-16
CA2693887A1 (en) 2009-01-22
JP2010533675A (ja) 2010-10-28
PE20091087A1 (es) 2009-07-20
RU2485119C2 (ru) 2013-06-20
IL202769A0 (en) 2010-06-30
AU2008277679A1 (en) 2009-01-22
HK1142323A1 (en) 2010-12-03

Similar Documents

Publication Publication Date Title
ECSP109966A (es) Derivados de 6-fenil-1h-imidazo-[4,5-c] piridina-4-carbonitrilo como inhibidores de catepsina
ECSP088654A (es) Derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo como inhibidores de la catepsina k y s
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
UY31065A1 (es) Heterociclos ciclicos
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
SV2010003767A (es) Compuestos pirazolicos 436
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
SV2008003037A (es) Derivados de amina
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY28752A1 (es) Agentes terapeuticos
MA33768B1 (fr) Triazolopyridines
ECSP066730A (es) Compuestos y procedimientos para uso
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
GEP20125459B (en) Compounds for inhibiting mitotic progression